IP Library Granted Patent US 7,482,463
Granted Patent B2
US 7,482,463 · App. 11/946,193 · Granted Jan 27, 2009

Amorphous form of esomeprazole salts

Assignee: Ranbaxy Laboratories Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,482,463
App. No.
11/946,193
Granted
Jan 27, 2009
Kind
B2
Abstract

The invention relates to an amorphous form of the salts of the (-) enantiomer or (S)-enantiomer of omeprazole, i.e., esomeprazole. The invention also relates to processes for preparing amorphous esomeprazole salts and pharmaceutical compositions that include the amorphous esomeprazole salts.

Claims (18)

1. A process for the preparation of a salt of the amorphous form of esomeprazole, the process comprising:

preparing a solution of a salt of esomeprazole in at least one organic solvent, wherein the organic solvent contains an organic amine or ammonia, and

recovering the salt of esomeprazole in the amorphous form from the solution thereof by the removal of the solvent.

2. The process of claim 1 , wherein a cation is selected from the group consisting of Na, Mg, Li, K, Ca, and N(R.).sub.4, where R is a hydrogen or an alkyl group with 1-4 carbon atoms.

3. The process of claim 2 , wherein the cation is Na.

4. The process of claim 2 , wherein the cation is Mg.

5. The process of claim 2 , wherein the cation is K.

6. The process of claim 2 , wherein the cation is Ca.

7. The process of claim 1 , wherein the solvent is at least one of a lower alkanol, ketone, ester, chlorinated solvent, acetonitrile or mixtures thereof.

8. The process of claim 7 , wherein the lower alkanol is selected from a primary, secondary or tertiary alcohol having from one to six carbon atoms.

9. The process of claim 7 , wherein the lower alkanol is methanol, ethanol, denatured spirit, n-propanol, isopropanol, n-butanol, isobutanol, and t-butanol or a mixture thereof.

10. The process of claim 7 , wherein the ketone is selected from acetone, 2-butanone, and 4-methylpentan-2-one or a mixture thereof.

11. The process of claim 7 , wherein the ester is selected from ethyl acetate, n-butyl acetate or a mixture thereof.

12. The process of claim 7 , wherein the chlorinated solvent is selected from chloroform, dichloromethane or a mixture thereof.

13. The process of claim 1 , wherein removing the solvent comprises one or more of distillation, distillation under vacuum, evaporation, spray drying, and freeze drying.

14. The process of claim 1 , wherein the salt of esomeprazole in an amorphous form is recovered from the solution by spray drying.

15. The process of claim 1 , wherein the salt of esomeprazole in an amorphous form is recovered from the solution by freeze-drying.

16. The process of claim 1 , further comprising additional drying of the product obtained.

Assignments (2)
MERGER Recorded Mar 28, 2016
From: RANBAXY LABORATORIES LIMITED
To: SUN PHARMACEUTICAL INDUSTRIES LIMITED
Reel/Frame 038274/0667 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2008
From: KHANNA, MAHAVIR SINGH; VIJAYARAGHAVAN, BAKTHAVATHSALAN; PRASAD, MOHAN; KUMAR, YATENDRA
To: RANBAXY LABORATORIES LIMITED
Reel/Frame 020384/0824 →
Priority Claims (1)
IN 1057/DEL/2002 · Oct 22, 2002 · national
Continuity (2)
Division 1069089700 · Oct 22, 2003
Related Publication 20080119654A1 · May 22, 2008